Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer


Excerpt from the Press Release: CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that patients from the INNATE Phase 2 trial in the ovarian cancer combination cohort with platinum resistant ovarian cancer…

Read More

Akamis Bio, Parker Institute for Cancer Immunotherapy, and Cancer Research Institute Announce Expanded Partnership to Advance Novel Treatments for Pancreatic Cancer


– Akamis Bio’s clinical-stage NG-350A tumor gene therapy to be included as a novel combination therapeutic agent in a new cohort of the REVOLUTION platform study – New cohort will assess the ability of NG-350A in combination with ipilimumab and standard of care chemotherapy to drive a CD40 agonist-mediated antitumor immune response in metastatic pancreatic…

Read More

Palisade Bio Promotes Robert McRae to Chief Operating Officer


Mr. McRae is an industry veteran with a proven track record of operational, clinical, and strategic business development execution Excerpt from the Press Release: Carlsbad, CA, Feb. 08, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the promotion…

Read More

Sonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human Primates


Excerpt from the Press Release: PRINCETON, NJ / ACCESSWIRE / February 1, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that two IND-enabling toxicology studies have been completed in non-human primates (NHPs) using its lead bifunctional therapeutic candidate. SON-1210 is a proprietary, bispecific…

Read More

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy


Recruitment ongoing in Europe, Asia-Pacific, and the U.S. for study of rapidly progressive Parkinsonian Disorder Excerpt from the Press Release: MELBOURNE, Australia AND SAN FRANCISCO, Jan. 25, 2023 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the…

Read More

Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)


Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs IgG4-RD is the first of several potential disease indications to be pursued for obexelimab given its unique non-depleting, B-cell inhibition Excerpt from the Press Release: WALTHAM, Mass., Jan.…

Read More

ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference


Excerpt from the Press Release: FREMONT, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Dr. Keith McBurnett, Professor of Psychiatry at the University of California San Francisco, presented the results of the…

Read More

Sonnet BioTherapeutics Announces Pharmacokinetic and Pharmacodynamic Data in a Phase 1 Dose-Escalation Trial of SON-1010


Excerpt from the Press Release: PRINCETON, NJ / ACCESSWIRE / January 19, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that pharmacokinetic (PK) profile simulation of SON-1010 dosing has been completed in its randomized, placebo-controlled Phase 1 clinical trial in healthy volunteers. Historically,…

Read More

Aitia and G3 Therapeutics Publish Results Identifying New Causal Biomarkers of Atherosclerotic Coronary Artery Disease (ASCAD), the Leading Cause of Morbidity and Mortality Worldwide


Excerpt from the Press Release: ATLANTA and SOMERVILLE, Mass., Jan. 12, 2023 /PRNewswire/ — G3 Therapeutics, a life sciences company that leverages large-scale multi-omic biological big data to develop life-changing therapeutics and diagnostics, and Aitia, the leader in the application of Causal AI and “Digital Twins” to discover and develop new drugs, today announced results…

Read More

Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial


mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death compared to KEYTRUDA monotherapy in stage III/IV melanoma patients with high risk of recurrence following complete resection Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical…

Read More